Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer

被引:6
作者
Shao, T. C.
Li, H.
Ittmann, M.
Cunningham, G. R.
机构
[1] Michael E DeBakey Vet Affairs Med Ctr, Res Serv 151, Dept Med, Houston, TX 77030 USA
[2] Michael E DeBakey Vet Affairs Med Ctr, Dept Pathol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[5] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
关键词
prostate; dutasteride; mice; transgenic; prostatic hyperplasia; prostatic neoplasms;
D O I
10.1016/j.juro.2007.05.118
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the effects of dutasteride for preventing or delaying prostate growth and neoplastic changes in a transgenic model of prostate cancer. Materials and Methods: Large probasin-large T antigen mice were treated for 4 or 8 weeks with dutasteride. The prostate and seminal vesicles were compared with those from intact and castrated large probasin-large T antigen mice and WT mice. Results: Dutasteride greatly decreased the transgene induced increase in prostate weight but castration caused greater reduction. Dutasteride inhibited type I and 2, 5alpha-reductase activities, decreased DNA and protein, and increased apoptotic bodies and TUNEL staining in the dorsolateral prostate. No evidence of poorly differentiated cancer was seen. Dutasteride did not decrease the weight of the androgen dependent levator ani or bulbocavernosus muscle. Conclusions: Dutasteride inhibited type 1 and 2, 5alpha-reductase activities, and decreased DNA and protein content of the dorsolateral. prostate without affecting androgen responsive muscle weight in large probasin-large T antigen mice. These studies provide support for the hypothesis that a 5alpha-reductase inhibitor inhibits the initiation and/or progression of clinical prostate cancers.
引用
收藏
页码:1521 / 1527
页数:7
相关论文
共 20 条
[1]   Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial [J].
Andriole, G ;
Bostwick, D ;
Brawley, O ;
Gomella, L ;
Tindall, D ;
Breed, S ;
Somerville, M ;
Rittmaster, R .
JOURNAL OF UROLOGY, 2004, 172 (04) :1314-1317
[2]  
Andriole GL, 2004, UROLOGY, V64, P537, DOI 10.1016/j.urology.2004.04.084
[3]  
Bonkhoff H, 1996, PROSTATE, V29, P261, DOI 10.1002/(SICI)1097-0045(199610)29:4<261::AID-PROS7>3.0.CO
[4]  
2-E
[5]   Prostate cancer management: (2) an update on locally advanced and metastatic disease [J].
Bott, SRJ ;
Birtle, AJ ;
Taylor, CJ ;
Kirby, RS .
POSTGRADUATE MEDICAL JOURNAL, 2003, 79 (937) :643-645
[6]  
BRUCHOVSKY N, 1996, J STEROID BIOCHEM, V59, P398
[7]   Chemoprevention of prostate carcinogenesis by DFMO and/or finasteride treatment in male wistar rats [J].
Esmat, AY ;
Refaie, FM ;
Shaheen, MH ;
Said, MM .
TUMORI, 2002, 88 (06) :513-521
[8]   THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA [J].
GORMLEY, GJ ;
STONER, E ;
BRUSKEWITZ, RC ;
IMPERATOMCGINLEY, J ;
WALSH, PC ;
MCCONNELL, JD ;
ANDRIOLE, GL ;
GELLER, J ;
BRACKEN, BR ;
TENOVER, JS ;
VAUGHAN, ED ;
PAPPAS, F ;
TAYLOR, A ;
BINKOWITZ, B ;
NG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1185-1191
[9]  
Kasper S, 1998, LAB INVEST, V78, pI
[10]   The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia [J].
McConnell, JD ;
Roehrborn, CG ;
Bautista, OM ;
Andriole, GL ;
Dixon, CM ;
Kusek, JW ;
Lepor, H ;
McVary, KT ;
Nyberg, LM ;
Clarke, HS ;
Crawford, ED ;
Diokno, A ;
Foley, JP ;
Foster, HE ;
Jacobs, SC ;
Kaplan, SA ;
Kreder, KJ ;
Lieber, MM ;
Lucia, MS ;
Miller, GJ ;
Menon, M ;
Milam, DF ;
Ramsdell, JW ;
Schenkman, NS ;
Slawin, KM ;
Smith, JA ;
Kusek, JW ;
Nyberg, LM ;
Briggs, JP ;
McConnell, JD ;
Crawford, ED ;
Homan, K ;
Donohue, R ;
Parker, D ;
Easterday, K ;
Robertson, K ;
Kaplan, S ;
Wentland, M ;
Hardy, L ;
Roehrborn, C ;
Ahrens, A ;
McConnell, J ;
Hall, D ;
Cutts, D ;
Carter, S ;
Waldrep, K ;
Schenkman, N ;
Sanetrik, K ;
Sihelnik, S ;
Zorn, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2387-2398